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It is known that atrial fibrillation (AF), the most common 
supraventricular cardiac arrhythmia (1), is associated 
with increased mortality and morbidity, with cerebral 
thromboembolism representing the most serious and 
threatening complication. Therefore, together with the 
adoption of either rate control—decreasing ventricular 
response by atrioventricular nodal-blocking drugs—
or rhythm control strategy—restoring sinus rhythm by 
anti-arrhythmic drugs (AADs) and/or atrial fibrillation 
transcatheter ablation (AFTCA), oral anticoagulation 
therapy (OAT) is mandatory for all patients with high 
thromboembolic risk (CHA2DS2-VASc ≥3 for females and 
≥2 for males) (2).
Recently, Saliba et al. (3) published the results of a large 
retrospective, cohort study comparing the occurrence of 
stroke/transient ischemic attack (TIA) and mortality in 
AF patients treated by primary catheter ablation (ablation 
cohort) compared to the remaining patients (non-ablation 
cohort), retrieving data from the Israel population-based 
electronic medical records (EMRs) database. From an initial 
sample of 43,041 adult AF patients (1,015 in the ablation 
cohort; 42,026 in the non-ablation cohort), a propensity 
score-matched sample of 4,741 patients (969 in the ablation 
group; 3,772 in the non-ablation group) was analysed. The 
cumulative incidence of stroke/TIA was significantly lower 
in the ablation group (P=0.002), with an incidence rate of 
2.1 compared to 3.26 per 100 person-years in the non-
ablation group. The corresponding CHA2DS2-VASc 
adjusted HR was 0.58 (95% CI, 0.43–0.72) for patients 
in the ablation group with respect to non-ablation group. 
Similarly, a reduction in the cumulative incidence of 
mortality was found (P<0.0001), with a CHA2DS2-VASc 
adjusted HR of 0.57 (95% CI, 0.47–0.66) in the ablation 
group compared to non-ablation group.
These results are intriguing and surely highlight the 
potential benefits deriving from AFTCA on a real-life 
setting. In particular, dealing with AFTCA effectiveness 
in decreasing stroke/TIA and mortality with respect to 
medically managed AF patients (on AADs or rate control 
drugs), this study supports AFTCA as first line approach in 
AF management. Even considering the limitations imposed 
by the observational nature of the study, the message 
conveyed is that AFTCA, compared to rate control or 
rhythm control by AADs, can decrease by 40% the risk of 
mortality and stroke/TIA. Translating this concept in terms 
of number needed to treat (NNT), we could affirm that in 
our clinical practice, by treating less than three AF patients 
by AFTCA (NNT 2.7) we avoid one cerebrovascular 
accident or a death. In some way it is even possible that this 
study, due to study design, has underestimated the impact of 
AFTCA on stroke/TIA and mortality. In fact, in the study 
of Saliba et al. the acute and long-term procedural success 
rate of AFTCA was not available. For this reason, patients 
with unsuccessful AFTCA have been anyway considered in 
the ablation group, trimming down the measure of AFTCA-
related reduction in cerebrovascular accidents and mortality. 
In addition, the included population is characterized by 
a high thromboembolic risk, as documented by the post 
propensity match mean CHA2DS2-VASc score of 3.6 
in both ablation and non-ablation group. It is plausible 
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that, in AF patients with a lower (CHA2DS2-VASc =0/1) 
thromboembolic risk, in whom AF is more commonly the 
solely thromboembolic risk factor, AFTCA impact on the 
reduction of stroke/TIA and mortality would result even 
greater.
“Rate or rhythm control for atrial fibrillation?”. This 
is the vexed clinical dilemma that afflicts cardiologists 
when facing the most common cardiac arrhythmia. Until 
about ten years ago, “rate vs rhythm control” was purely 
a matter of “nodal-blocking drugs vs AADs”. In this pre-
AFTCA era, two ground-breaking studies tried to solve 
the dilemma: the RACE (4) and the AFFIRM study (5). In 
both studies, rhythm control strategy with AADs did not 
offer any survival advantage over rate control strategy. On 
the contrary, rhythm control strategy was characterized by 
more complications and hospitalisations, due to the intrinsic 
toxicities of AADs. However, successive observational 
studies suggested that rhythm-control therapy with AADs 
could be superior to rate control, with the benefit emerging 
only on the long run, both concerning mortality (6) than 
cerebrovascular events (7). In a study by Ionescu-Ittu 
et al. (6), the mortality rate in a rhythm control group 
decreased steadily with respect to the rate control group 
only after the first 5 years of follow up (during which no 
differences between medical rhythm control and rate 
control therapy were found). A likely explanation of this 
phenomenon is that during the first years of medical rhythm 
control therapy the potential toxicities of the AADs could 
balance the intrinsic survival advantage granted by rhythm 
control itself, resulting in no net survival advantages of the 
rhythm over rate control.
In the last decade, instead, AFTCA, introduced in 
clinical practice at the end of the past century, reached 
a wide diffusion and a recognised role as an effective 
non-medical rhythm control approach. The rise of 
this procedure reignited the never faded debate on AF 
management, in particular since AFTCA is devoid of the 
intrinsic toxicities of AADs and is superior over AADs 
in maintaining sinus rhythm (8,9). To date, only few 
observational studies have assessed the effect of AFTCA 
on long-term outcomes such as stroke/TIA and mortality 
(10-13). All these studies indicated a reduced burden of 
mortality and cerebrovascular events in AF patients treated 
with AFTCA, but, in addition to the observational design 
(due to which certain conclusions may not be taken), 
they are characterized by limited generalizability. In this 
context, the study from Saliba et al. (3), by providing 
real clinical practice data with strong generalizability, 
adds significant data. In any case, to prove a cause-effect 
relationship in favour of AFTCA in terms of mortality and 
stroke/TIA we need to wait for large randomized clinical 
trials (RCTs) data. In the next few years, an ongoing RCT 
will probably provide the medical community with the 
elements to solve this clinical dilemma: the “Catheter 
Ablation vs Anti-arrhythmic Drug Therapy for Atrial 
Fibrillation Trial (CABANA)” (14). This study was 
designed to prove that AFTCA is superior to both rate and 
rhythm control drug therapy in AF patients by decreasing 
the incidence of the composite endpoint of total mortality, 
disabling stroke, serious bleeding, or cardiac arrest. Should 
the results support the superiority of the former, AFTCA 
will probably become the first line treatment of AF. In 
the meantime, the late-breaking results of a completed 
RCT, the “Catheter Ablation vs. Standard Conventional 
Treatment in Patients With LV Dysfunction and AF 
(CASTLE-AF)” (15), were recently presented at the 
European Society of Cardiology (ESC) 2017 Congress. 
In this trial, confirming previous non-randomized 
evidences (16) ,  AFTCA, in patients  with AF and 
concomitant systolic heart failure (HF), provides significant 
benefit with respect to conventional drug treatment (rhythm 
and rate control drugs) in terms of mortality (HR, 0.53; 
95% CI: 0.32–0.86) and hospitalisation for HF (HR, 0.56; 
95% CI: 0.37–0.83).
Hence, waiting for evidence on the long-term impact of 
AFTCA in the general AF population, as clear as for the 
subpopulation of AF patients with concomitant HF, the 
following issues weigh consideration.
OAT discontinuation after AFTCA
Proven that the benefit of OAT for thromboembolic risk 
reduction is considered to outweigh the measurable risk 
of bleeding in most AF patients, it is still debated whether 
OAT should be continued after an apparently successful 
AFTCA. Due to lack of systematic evidence, current 
guidelines recommend that decision of maintaining OAT 
after catheter ablation should follow general anticoagulation 
recommendations, regardless of the presumed rhythm 
outcome (2). Anyway, growing observational data hint 
that in several patients the risk of bleeding could outweigh 
the risk of thromboembolic events, thus favouring OAT 
discontinuation after a successful AFTCA. A recent 
study from Karasoy et al. (17) demonstrated that OAT 
discontinuation was not associated with significantly 
increased thromboembolic risk neither in low- nor in high-
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risk patients, while OAT maintenance was associated with 
higher incidence rates of serious bleeding compared with 
OAT discontinuation. An Italian multicentre observational 
study confirmed these findings (18): 1,500 patients were 
retrospectively divided into three groups: group A—
AFTCA maintaining antivitamin K (AVK); group B—
AFTCA discontinuing AVK; group C—rate control and 
AVK. Thromboembolic events did not differ between 
the groups (5/500, 1% group A; 7/500, 1.4% group B; 
11/500, 2.2% group C; P=0.45), while haemorrhagic events 
were greater in group A (9/500, 1.8%) and C (12/500, 
2.4%) than in group B (no events; P=0.003). Thus, in this 
experience, OAT maintenance with antivitamin K (AVK) 
following AFTCA eventually conferred a haemorrhagic 
risk greater to the thromboembolic protective effect. RCTs 
are mandatory to support these findings, possibly paving 
the way for a standardised approach first to detect AF 
following the procedure, and, consequently, decide which 
AF patient could stop OAT in order to prevent the extra-
risk of bleedings. In this sense, the work from Saliba et al. (3) 
lacks details regarding OAT prosecution after AFTCA: in 
particular, it would have been interesting, in such a large 
study, to assess among the patients in the ablation group the 
distribution of cerebral ischemic events stratified by OAT 
recommendation.
Timing of AFTCA
Another relevant and yet unanswered issue regards the 
proper time to perform AFTCA. Waiting for ongoing 
RCTs which will surely shed light on this issue, an 
observational study, although presenting the bias of 
having been performed in our “highly motivated AFTCA 
rhythm control centre”, clearly indicates that the long-
term progression from non-permanent (paroxysmal and 
persistent) to permanent AF is reduced if AFTCA is 
performed early (paroxysmal phase) in the natural history 
of the disease (19): in fact, after a median follow-up of 
64 months, AF progression to a permanent form was 
documented in 2.7%, 10.0% and 14.6% of patients with 
respectively baseline paroxysmal, persistent and long-
standing persistent AF. Also after very long term follow up 
(10 years) this trend is confirmed with a reduced recurrence 
rate in patients with baseline paroxysmal over persistent 
AF (20). Given that long arrhythmia duration is known 
to cause consequent structural remodelling of the left 
atrial substrate, increased tissue fibrosis and intra-atrial 
conduction disturbances perpetuating the arrhythmia, this 
finding is quite intuitive, however it is not, to date, reflected 
in clear clinical recommendations. As earlier AFTCA 
is performed the better it would be for AF patients in 
respect to relevant long-term outcomes, such as death and 
stroke; this statement should not remain just an intriguing 
hypothesis.
AF and dementia
In the past few years, it has emerged that AF, even in 
absence of clinically relevant ictus or TIAs, relates to 
an increased risk of dementia/cognitive decline (21). 
Different mechanisms have been proposed to explain this 
independent association, such as silent cerebral ischemia 
(SCI), cerebral microbleeds (CMBs) and an altered cerebral 
blood flow during AF. Our group previously demonstrated 
that patients with paroxysmal and persistent AF have a 
higher prevalence and number of areas of SCI—small 
hyperintense T2-weighted cerebral MR lesions—than 
healthy individuals and this related to worse cognitive 
performance than subjects in sinus rhythm (22), possibly 
due to cardiac microembolisms. An increase burden of 
CMBs can also be involved in the genesis of the AF-
related cognitive impairment, in particular in those patients 
on OAT (23). Again, understanding whether and when 
OAT could be stopped in AF patients with sinus rhythm 
restoration would help in preventing this extra brain 
damage. Finally, AF per se causes an altered cerebral blood 
flow. We recently demonstrated in a computational study 
that AF induces transient hypoperfusions and hypertensive 
events in the cerebral circulation (24,25), suggesting that 
the chronic occurrence of such critical hemodynamic events 
explains the genesis of a subgroup of non-microembolic 
SCI and non-OAT-related CMBs. In this sense, considering 
that AF rhythm status is independently associated with 
an increased risk of cognitive impairment/dementia, a 
procedure such as AFTCA, characterized by the lowest 
number of AF recurrences in the long-term especially when 
performed early in the history of the disease, may surely 
prevent, compared to a rate control strategy, the proportion 
of brain damage directly related to the AF-induced cerebral 
hemodynamics.
In conclusion, in addition to the superiority in 
maintaining sinus rhythm when compared to AADs, 
growing clinical evidence points towards long-term 
protective effects of AFTCA in terms of mortality and 
cerebral thromboembolic events (Figure 1). Should the 
previous several observational findings be confirmed by the 
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ongoing RCTs, AFTCA will become the mainstay first-step 
therapy for AF.
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